Product Description
Samidorphan (SAM), a mu-opioid receptor antagonist, has gained interest due to its favorable pharmacokinetic and pharmacodynamic profile. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31523568/)
Mechanisms of Action: OPRM Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Sublingual
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: Alkermes
Company Location: DUBLIN 4 L2 00000
Company CEO: Richard F. Pops
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ALKS 3831-112 | P1 |
Completed |
Healthy Volunteers |
2022-11-19 |
28% |